• Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact

Barry A. Friedman, PhD LLC

FDA Regulatory Compliance for the Pharmaceutical, Biotechnology and Medical Device Arenas

AMERICAN NATIONAL RED CROSS RECEIVES ADVERSE DETERMINATION LETTER (1/13/12)

January 27, 2012 By Barry Friedman Leave a Comment

FAILURE OF THE ARC TO MEET REQUIREMENTS YIELDS OVER 9 MILLION DOLLAR FINE 

From April through October 2010, United States Food and Drug Administration (FDA) investigators inspected sixteen American National Red Cross (ARC) Blood Services facilities and observed significant violations of the law, regulations, and the Amended Consent Decree of Permanent Injunction, entered on April 15, 2003 (Decree). At the conclusion of each inspection, the investigators issued Forms FDA 483, Inspectional Observations (FDA 483),

The Decree requires ARC to establish and properly implement appropriate quality assurance (QA) and quality control (QC) measures. Proper QA and QC programs by blood establishments include measures to prevent, detect, investigate, evaluate, and correct errors. The goals of these programs include preventing the distribution of unsuitable blood products, and preventing the causes of recurrent problems. The proper implementation of a strong QA program is essential to ensure the safety of the nation’s blood supply.

The FDA during their 2010 inspections found a number of Decree Violations to include:

1)  Inadequate managerial Control

2)  Inadequate QA

3)  Failure to Comply with Reporting Requirements

4)  Inadequate Problem Management

5)  Failure to Follow SOP

6)  Failure to Follow Manufacturer’s Instructions

7)  Inadequate Training

8)  Inadequate Recordkeeping

Because of these findings, the FDA has determined that ARC did not comply with the law and under paragraph IX is fining the ARC a total of $9,592,000.

Please read the entire Adverse Determination Letter at

http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofGlobalRegulatoryOperationsandPolicy/ORA/ORAElectronicReadingRoom/UCM287834.pdf

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)

Related

Filed Under: Adverse Determination Letter, FDA Compliance, Regulatory Compliance Tagged With: Adverse Determination Letter, American Red Cross, ARC, Consent Decree, FDA Form 483. SOPs, Fine, QA, QC, recordkeeping, training

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

New Reader? Learn More

Connect With Me:

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Webinar Registration & Information

FREQUENTLY ASKED QUESTIONS:

FDA Form 483 Frequently Asked Questions

USP General Chapter

USP General Chapter 62, Part II

TOP OBSERVATIONS:

FDA’s CDER LISTING OF TOP NINETEEN OBSERVATIONS FOR 2014

FDA CDER Most Frequent Form FDA 483 Observations Fiscal Year 2012

CDER MOST FREQUENTLY CITED DRUG OBSERVATIONS – FISCAL YEAR 2010

Top Posts:

Top Posts for 2012

Top Posts for 2013

Top Posts Year To Date

Recent Posts

  • Upcoming Microbiological Webinars
  • Microbiological Webinars
  • Microbiological Webinars 2020 (Upcoming)
  • General Chapter (USP<60>) on B. cepacia Complex to Issue December 1, 2019
  • Les Produits Chimiques B.G.R., Inc. Receives FDA Warning Letter (07/24/2018) for Failure to Perform Laboratory Testing

Categories

follow us in feedly
  • Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact
  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Thank You For Visiting Barry A. Friedman, PhD LLC - 2015

Welcome To My Blog!
Please enter your name and email below to receive my newsletter.
Your information will *never* be shared or sold to a 3rd party.